 |
|
|
| |
News
Return to News
Argos Therapeutics to Discuss Automated Manufacturing Process
for its Arcelis™ Personalized Immunotherapy Platform
-Presentation at the Cambridge Healthtech Institute’s Advances in Cancer
Vaccines Conference-
Durham, NC– August 5, 2008 — Argos Therapeutics today announced that Dr. Fred
Miesowicz, Ph.D., Chief Operating Officer, will present details on the Company´s automated
manufacturing process for its Arcelis™ platform, a technology for creating personalized
immunotherapies for HIV, other infectious diseases, and cancer. The presentation will take place
on August 14, 2008 at the Cambridge Healthtech Institute´s conference on Advances in Cancer
Vaccines, part of the ImVacS Immunotherapeutics and Vaccine Summit, in Cambridge, MA.
Dr. Miesowicz´s presentation will address automated systems for delivering personalized, RNAloaded,
dendritic cell-based immunotherapies on a commercial scale. Automated devices for
cellular and RNA processing would have the potential for broad applicability across disease
indications amenable to cell-based immunotherapy. Argos has developed working prototypes of
equipment capable of automating both cellular and RNA processing. The automated system
includes three standalone units: an RNA processing unit and two cellular processing units that use
functionally closed disposables. Development advantages for this approach include that it is
commercially feasible, involves routine clinical procedures, provides years of therapy with a
single production run, and benefits from a clear regulatory path. These automated devices
produce autologous immunotherapies at higher throughput and with a lower cost of goods versus
manual processing methods.
Additional details on the Advances in Cancer Vaccines conference can be found at
http://www.healthtech.com/imt/overview.aspx?c=551.
About Argos Therapeutics, Inc.
Argos is an immunotherapy company developing new treatments for cancer, infectious and
autoimmune diseases, and transplantation rejection. The Company has generated multiple
platform technologies and a diverse pipeline of products based on its expertise in the biology of
dendritic cells — the master switch that turns the immune system on or off.
www.argostherapeutics.com
Contacts:
Jennifer Greenleaf
MacDougall Biomedical Communications
(781) 235-3060
Jeff Abbey
Argos Therapeutics
(919) 287-6308
print friendly version
# # #
|
|
 |
|
